About Scope Biosciences
Scope Biosciences is a Healthcare company based in Wageningen (Netherlands) founded in 2019 by Stijn Prinsen, Bart Scholten, Niek Savelkoul, and Jurre Steens. CRISPR-Cas based diagnostic platform is developed for nucleic acid detection. Scope Biosciences has raised $1.69 million across 3 funding rounds from investors including European Union, GenDx and Oost NL. Scope Biosciences offers products and services including scope Dx assay and CRISPR-Cas Test. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its legal entity is Scope Biosciences B.V.
Company details
Scope Biosciences was founded in 2019 in Wageningen, Netherlands. The scopeDx platform is developed using proprietary Type III CRISPR-Cas nucleases. Nucleic acid sequences are detected to identify genetic material with single nucleotide specificity. Operations are centered in the biotechnology sector, focusing on diagnostic tools for research and clinical applications. Co-founders include Stijn Prinsen, Bart Scholten, Niek Savelkoul, and Jurre Steens.
- Headquarters Wageningen, Netherlands
- Founders Stijn Prinsen, Bart Scholten, Niek Savelkoul, Jurre Steens
- SectorsHealthcare
- Email••••••••
- Website scopebio.com
- Social LinkedIn X Facebook
- Legal Name Scope Biosciences B.V.
- Total Equity Funding$1.69M (USD)
in 3 rounds
- Latest Funding Round$531.52K (USD), Seed
Oct 2023
- InvestorsEuropean Union
& 3 more
Products & Services of Scope Biosciences
Scope Biosciences offers a comprehensive portfolio of products and services, including scope Dx assay and CRISPR-Cas Test.
CRISPR-Cas based test for detecting genetic material onsite
Simple onsite tool for healthcare and agriculture genetic analysis
Funding Insights of Scope Biosciences
Scope Biosciences has successfully raised a total of $1.69M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $531.52 thousand completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.69M
- Total Rounds 3
- Last Round Seed — $531,520
- First Round $1.16M
(Nov 2021)
- Investors Count 4
All 3 funding rounds of Scope Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $531,520 | Seed | – | Tech Transfer, Oost NL | – |
| Sep 2022 | Grant | – | – | ||
| Nov 2021 | $1.16M | Seed | – | GenDx | – |
4 investors in total: 4 institutional.
Investors in Scope Biosciences
Scope Biosciences has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, GenDx and Oost NL.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sector-agnostic VC firm investing in geographies such as the Netherlands | 2003 | oostnl.nl | Apeldoorn, Netherlands | |
| tech-transfer.nl | ||||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Develops and markets a line of In Vitro Diagnostic (IVD) tests and services, analysis software and education | 2005 | gendx.com | Utrecht, Netherlands |
Investor details for Scope Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Scope Biosciences
4 people are tracked at Scope Biosciences (4 in leadership).
| Name | Role | Group |
|---|---|---|
Stijn Prinsen | Co-Founder | Leadership |
Bart Scholten | Co-Founder | Leadership |
Niek Savelkoul | Co-Founder | Leadership |
Jurre Steens | Co-Founder | Leadership |
Complete people profiles for Scope Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Scope Biosciences
3 dated milestones of Scope Biosciences across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Scope Biosciences is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Seed, of $532K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Scope Biosciences
Complete news archive for Scope Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scope Biosciences
Scope Biosciences was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Scope Biosciences is headquartered in Wageningen, Netherlands. It is registered at Wageningen, Gelderland, Netherlands.
Scope Biosciences is a funded company, having raised a total of $1.69M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.16M, raised on Nov 2021.
Scope Biosciences was founded in 2019 in Wageningen, Netherlands. The scopeDx platform is developed using proprietary Type III CRISPR-Cas nucleases. Nucleic acid sequences are detected to identify genetic material with single nucleotide specificity. Operations are centered in the biotechnology sector, focusing on diagnostic tools for research and clinical applications. Co-founders include Stijn Prinsen, Bart Scholten, Niek Savelkoul, and Jurre Steens.
Scope Biosciences offers scope Dx assay and CRISPR-Cas Test.
Scope Biosciences has 4 investors. Key investors include European Union, GenDx, Oost NL, and Tech Transfer.
Scope Biosciences operates through Scope Biosciences B.V..